array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2444) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(101) "Vestmark Advisory Solutions Inc. Acquires 164 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(259) "Vestmark Advisory Solutions Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 57.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(139) "http://www.defenseworld.net/2023/08/18/vestmark-advisory-solutions-inc-acquires-164-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1d072491-7466-4e87-b7e9-ad55a37dee8c" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-08-18" ["categories"]=> array(5) { [0]=> string(12) "Stock Market" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Regulations" [3]=> string(11) "Acquisition" [4]=> string(14) "Issuing Shares" } } [1]=> array(7) { ["title_en"]=> string(87) "Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon" ["snippet_en"]=> string(171) "Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration." ["url"]=> string(116) "https://www.investopedia.com/regeneron-shares-jump-as-the-firm-expects-an-fda-decision-on-eye-treatment-soon-7569554" ["image_url"]=> NULL ["source"]=> string(16) "investopedia.com" ["publication_date"]=> string(10) "2023-08-03" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(14) "Issuing Shares" [2]=> string(12) "Stock Market" } } [2]=> array(7) { ["title_en"]=> string(111) "Nisa Investment Advisors LLC Has $19.98 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Nisa Investment Advisors LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 19.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,312 shares of the biopharmaceutical compa" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2023-07-21/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a103b9e3-e9ba-4af2-9a7f-45c1afb663db" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-07-22" ["categories"]=> array(7) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(12) "Stock Market" [2]=> string(11) "Regulations" [3]=> string(14) "Issuing Shares" [4]=> string(18) "General Investment" [5]=> string(19) "Investment Requests" [6]=> string(31) "Financial Update/Profit Warning" } } [3]=> array(7) { ["title_en"]=> string(110) "Bayer shares continue to fall - buy now because of the favorable valuation or throw them out of the portfolio?" ["snippet_en"]=> string(90) "Bayer shares are in a very important place on the chart. Should investors buy or sell now?" ["url"]=> string(159) "https://www.boerse-online.de/nachrichten/aktien/bayer-aktie-sackt-weiter-ab-jetzt-wegen-guenstiger-bewertung-kaufen-oder-aus-dem-depot-schmeissen-20334657.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/829511e6-4b92-4467-8195-64aae4723f97" ["source"]=> string(16) "boerse-online.de" ["publication_date"]=> string(10) "2023-06-28" ["categories"]=> array(10) { [0]=> string(12) "Stock Market" [1]=> string(9) "Valuation" [2]=> string(24) "Stock Research & Ratings" [3]=> string(25) "Business Model Resilience" [4]=> string(9) "Investors" [5]=> string(11) "Acquisition" [6]=> string(14) "Issuing Shares" [7]=> string(18) "General Investment" [8]=> string(15) "Market Movement" [9]=> string(16) "Share Repurchase" } } [4]=> array(7) { ["title_en"]=> string(84) "D.A. Davidson & CO. Sells 14 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(252) "D.A. Davidson & CO. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(120) "https://www.defenseworld.net/2023/05/01/d-a-davidson-co-sells-14-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c3417438-8e22-4c32-b151-0100da7aa580" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-05-01" ["categories"]=> array(4) { [0]=> string(11) "Acquisition" [1]=> string(14) "Issuing Shares" [2]=> string(10) "Divestment" [3]=> string(12) "Stock Market" } } [5]=> array(7) { ["title_en"]=> string(89) "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by National Bank of Canada FI" ["snippet_en"]=> string(302) "National Bank of Canada FI raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 53.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,426 shares of the biopharmaceutical company’ s stock after acquiring an additional 5,036 shares" ["url"]=> string(129) "https://www.defenseworld.net/2023/04/05/regeneron-pharmaceuticals-inc-nasdaqregn-shares-bought-by-national-bank-of-canada-fi.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dd5ecedb-fcca-494a-aff9-b5749cea00e4" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-04-05" ["categories"]=> array(2) { [0]=> string(14) "Issuing Shares" [1]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(73) "Sanofi, Regeneron Shares Pop On Big News About COPD Treatment - ValueWalk" ["snippet_en"]=> string(150) "Shares of Sanofi (NASDAQ:SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) finished with a gain of 9.68%" ["url"]=> string(87) "https://www.valuewalk.com/sanofi-regeneron-shares-pop-on-big-news-about-copd-treatment/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/0d0f8845-1c97-4e8b-8aeb-d69c8c9261a7" ["source"]=> string(13) "valuewalk.com" ["publication_date"]=> string(10) "2023-03-28" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(14) "Issuing Shares" [2]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(61) "Sanofi, Regeneron Shares Pop On Big News About COPD Treatment" ["snippet_en"]=> string(280) "Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies’ jointly developed medication Dupixent.In Phase 3 clinical trials, Dupixent red" ["url"]=> string(92) "https://www.nasdaq.com/articles/sanofi-regeneron-shares-pop-on-big-news-about-copd-treatment" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-03-27" ["categories"]=> array(2) { [0]=> string(14) "Issuing Shares" [1]=> string(12) "Stock Market" } } [8]=> array(7) { ["title_en"]=> string(100) "Moore Capital Management LP Purchases 18,264 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(217) "Moore Capital Management LP raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 77.0% in the third quarter, according to the company in its most recent filing with the SEC." ["url"]=> string(139) "https://www.defenseworld.net/2023/03/09/moore-capital-management-lp-purchases-18264-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/32fb6ad7-8779-4da8-a0b3-8a25c21ad76f" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-03-09" ["categories"]=> array(1) { [0]=> string(14) "Issuing Shares" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(197) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(193) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(152) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(101) } [4]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(95) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(83) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(70) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(61) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(51) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(50) } [10]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(46) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(44) } [12]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(35) } [14]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [15]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [16]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(33) } [17]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(32) } [18]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [19]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(30) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(29) } [23]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(20) } [29]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc